BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Angeion Corporation (ANGN)'s Medical Graphics Business Offers Additional Choice of Diffusion Technology


2/7/2012 9:54:24 AM

SAINT PAUL, Minn., Feb. 7, 2012 /PRNewswire/ -- Medical Graphics Corporation, a subsidiary of Angeion Corporation (NASDAQ: ANGN), now offers hospitals, healthcare clinics and private practices assessing pulmonary function, Real Time Diffusion (RTD) based on MultiGas Technology, delivering rapid measurement, clinically significant graphic data and immediate results. Known globally for Reference Standard Gas Chromatography, the MedGraphics® brand now provides choice of diffusion technology: both meet or exceed International guidelines and are verifiable by Hans Rudolph DLco Simulator recognized as the Laboratory Quality Control for single-breath diffusion systems.

"We are delighted to provide our worldwide customers choice between two superb technologies for single breath assessments further expanding our cardiorespiratory diagnostic services," said Gregg O. Lehman, Ph.D., Angeion's President and Chief Executive Officer. "With our proprietary technology platform and real-time sensor quality assurance, RTD MultiGas Technology provides accurate, immediate results, eliminating the need of repeating tests. We believe that the addition of RTD to our product family will provide access to markets which MedGraphics® may have been previously excluded."

For both new and existing customers, RTD MultiGas Technology provides cost savings in time, consumables and increased quality, allowing customers to test more patients, with less costs and higher confidence. RTD MultiGas Technology is available as a diffusion option for MedGraphics Ultima PF System and award-winning Platinum Elite Series Body Plethysmograph (body box).

MedGraphics systems provide essential clinical information to healthcare professionals through non-invasive cardiopulmonary assessment to improve care of patients in leading hospitals, clinics, and physician offices throughout the U.S. and in more than 75 countries.

MedGraphics portfolio includes:

  • Pulmonary function from simple spirometry tests (breath flow and volume) to plethysmography for advanced diagnostic assessments;
  • Exercise assessment in rehabilitation and therapeutic monitoring centers for evaluating respiratory and cardiac capacity to perform activities of daily living; and
  • Indirect Calorimetry combined with respiratory measurements to determine essential nutritional requirements for patients in critical care/cardiac units.

MedGraphics products incorporate information management and connectivity solutions for electronic medical record systems to improve workflow and enhance data access.

About Angeion Corporation
Founded in 1986, Angeion Corporation acquired Medical Graphics Corporation in December 1999. Medical Graphics develops, manufactures and markets non-invasive cardiorespiratory diagnostic systems that are sold under the MedGraphics (www.medgraphics.com) and New Leaf (www.newleaffitness.com) brand names. These cardiorespiratory product lines provide solutions for disease detection, integrated care, and wellness across the entire spectrum of health whether managing chronic illness, promoting fitness, or training for the Olympics. The Company's products are sold internationally through distributors and in the United States through a direct sales force that targets heart and lung specialists located in hospitals, university-based medical centers, medical clinics and physicians' offices, pharmaceutical companies, medical device manufacturers, clinical research organizations, health and fitness clubs, personal training studios, and other exercise facilities. For more information about Angeion, visit www.angeion.com.

Forward Looking Statements
Press releases and other statements by Angeion may contain forward-looking statements about Angeion's future financial results and business prospects that by their nature involve substantial risks and uncertainties. You can identify these statements by the use of words such as "anticipate," "believe," "estimate," "expect," "project," "intend," "plan," "will," "target," and other words and terms of similar meaning in connection with any discussion of future operating or financial performance or business plans or prospects. Our actual results may differ materially depending on a variety of factors including: (1) national and worldwide economic and capital market conditions; (2) continuing cost-containment efforts in our hospital, clinics, and office market; (3) any changes in the patterns of medical reimbursement that may result from national healthcare reform; (4) our ability to successfully operate our business, including successfully converting our increasing research and development expenditures into new and improved cardiorespiratory diagnostic products and services and selling these products and services under the MedGraphics and New Leaf brand names into existing and new markets; (5) our success in executing our new strategic plan, developing new products and entering new markets; (6) our ability to complete our software development initiatives and migrate our MedGraphics and New Leaf platforms to a next generation technology; (7) our ability to maintain our cost structure at a level that is appropriate to our near to mid-term revenue expectations and that will enable us to increase revenues and profitability as opportunities develop; (8) our ability to achieve constant margins for our products and consistent and predictable operating expenses in light of variable revenues from our clinical research customers; (9) our ability to expand our international revenue through our distribution partners and our Milan, Italy representative branch office; (10) our ability to successfully defend ourselves from product liability claims related to our cardiorespiratory diagnostic products and claims associated with our prior cardiac stimulation products; (11) our ability to defend our existing intellectual property and obtain protection for intellectual property we develop in the future; (12) our ability to develop and maintain an effective system of internal controls and procedures and disclosure controls and procedures and (13) our dependence on third-party vendors. Additional information with respect to the risks and uncertainties faced by the Company may be found in, and the above discussion is qualified in its entirety by, the other risk factors that are described from time to time in the Company's Securities and Exchange Commission reports, including the Annual Report on Form 10-K for the year ended October 31, 2011.

Contact:

Gregg O. Lehman, Ph.D.

Joe Dorame, Robert Blum, Joe Diaz

Angeion

Lytham Partners, LLC

Chief Executive Officer and President

(602) 889-9700

(651) 484-4874

angn@lythampartners.com

SOURCE Angeion Corporation



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->